Archived COVID-19 Vaccination Schedules

This web page is archived for historical purposes and is no longer being updated. Please go to CDC Home or use the A-Z Index or Search for more recent information.

The August 22, 2022 COVID-19 vaccination schedules below were the most recent revision to the schedules prior to the initial authorization of bivalent mRNA COVID-19 boosters on August 31, 2022. They should be used for historical and research purposes only.

CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States should be consulted for current COVID-19 vaccination schedules and guidance. The Advisory Committee on Immunization Practices (ACIP) COVID-19 vaccine recommendations provide additional information.

ARCHIVED COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised, August 22, 2022

6 months through 11 years

COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised: Aged 6 months through 11 years
Manufacturer Age
group
Total number of doses recommended Number of primary doses* Number of booster doses† Interval between 1st and 2nd dose‡ Interval between 2nd and 3rd dose Interval between 3rd and 4th dose
Moderna 6 months–5 years 2 2 NA 4–8 weeks NA NA
Moderna 6–11 years 2 2 NA 4–8 weeks NA NA
Pfizer-BioNTech 6 months–4 years 3 3  NA 3–8 weeks At least 8 weeks NA
Pfizer-BioNTech 5–11 years 3 2 1 3–8 weeks At least 5 months NA

 

12 through 17 years

COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised: Aged 12 through 17 years
Manufacturer Age
group
Total number of doses recommended Number of primary doses* Number of booster doses† Interval between 1st and 2nd dose‡ Interval between 2nd and 3rd dose Interval between 3rd and 4th dose
Moderna 12–17 years 2 2 NA 4–8 weeks NA NA
Novavax 12–17 years 2 2 NA 3–8 weeks NA NA
Pfizer-BioNTech 12–17 years 3 2 1 3–8 weeks At least 5 months NA

18 years and older

COVID-19 vaccination schedule for people who are NOT moderately or severely immunocompromised: Aged 18 years and older†
Manufacturer Age
group
Total number of doses recommended Number of primary doses* Number of booster doses† Interval between 1st and 2nd dose‡ Interval between 2nd and 3rd dose Interval between 3rd and 4th dose
Moderna 18–49 years 3 2 1 4–8 weeks At least 5 months NA
Moderna 50 years and older 4 2 2 4–8 weeks At least 5 months At least 4 months
Novavax 18 years and older 2 2 NA 3–8 weeks NA NA
Pfizer-BioNTech 18–49 years 3 2 1 3–8 weeks At least 5 months NA
Pfizer-BioNTech 50 years and older 4 2 2 3–8 weeks At least 5 months At least 4 months
Janssen 18–49 years 2 1 1§ At least 2 months NA NA
Janssen 50 years and older 3 1 2 At least 2 months At least 4 months NA

Footnotes

Abbreviation: NA = not authorized

*For primary series vaccination, Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are recommended. Janssen COVID-19 Vaccine should only be used in limited situations.

For booster vaccination, Moderna and Pfizer-BioNTech are recommended and must be used for the second booster dose. Janssen COVID-19 Vaccine should only be used in limited situations. Currently, a booster dose using any COVID-19 vaccine is not authorized for people ages 6–17 years who receive a Moderna primary series or people ages 12 years and older who receive a Novavax primary series.

An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis/pericarditis associated with these vaccines. A shorter interval (3 weeks for Novavax and Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 Community Levels or an individual’s higher risk of severe disease.

§People ages 18–49 years who received Janssen COVID-19 Vaccine as both their primary dose and first booster dose may receive a second booster dose using an mRNA vaccine at least 4 months after the first booster dose.

ARCHIVED COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised, August 22, 2022

6 months through 11 years

COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised: Aged 6 months through 11 years
Manufacturer Age
group
Total number of doses recommended Number of primary doses* Number of booster doses† Interval between 1st and 2nd dose Interval between 2nd and 3rd dose Interval between 3rd and 4th dose Interval between 4th and 5th dose
Moderna 6 months–5 years 3 3 NA 4 weeks At least 4 weeks NA NA
Moderna 6–11 years 3 3 NA 4 weeks At least 4 weeks NA NA
Pfizer-BioNTech 6 months–4 years 3 3  NA 3 weeks At least 8 weeks NA NA
Pfizer-BioNTech 5–11 years 4 3 1 3 weeks At least 4 weeks At least 3 months NA

 

12 through 17 years

COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised: Aged 12 through 17 years
Manufacturer Age
group
Total number of doses recommended Number of primary doses* Number of booster doses† Interval between 1st and 2nd dose Interval between 2nd and 3rd dose Interval between 3rd and 4th dose Interval between 4th and 5th dose
Moderna 12–17 years 3 3 NA 4 weeks At least 4 weeks NA NA
Novavax 12–17 years 2 2 NA 3 weeks NA NA NA
Pfizer-BioNTech 12–17 years 5 3 2 3 weeks At least 4 weeks At least 3 months At least 4 months

18 years and older

COVID-19 vaccination schedule for people who ARE moderately or severely immunocompromised: Aged 18 years and older†
Manufacturer Age
group
Total number of doses recommended Number of primary doses* Number of booster doses† Interval between 1st and 2nd dose Interval between 2nd and 3rd dose Interval between 3rd and 4th dose Interval between 4th and 5th dose
Moderna 18 years and older 5 3 2 4 weeks At least 4 weeks At least 3 months At least 4 months
Novavax 18 years and older 2 2 NA 3 weeks NA NA NA
Pfizer-BioNTech 18 years and older 5 3 2 3 weeks At least 4 weeks At least 3 months At least 4 months
Janssen 18 years and older 4 2
(1 Janssen, followed by 1 mRNA)
2 At least 4 weeks At least 2 months At least 4 months NA

Footnotes

Abbreviation: NA = not authorized

*For primary series vaccination, Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines are recommended; Janssen COVID-19 Vaccine should only be used in limited situations.

For booster vaccination, Moderna and Pfizer-BioNTech are recommended and must be used for the second booster dose. Janssen COVID-19 Vaccine should only be used in limited situations. Currently, a booster dose using any COVID-19 vaccine is not authorized for people ages 6–17 years who receive a Moderna primary series or people ages 18 years and older who receive a Novavax primary series.